News coverage about Regeneron Pharmaceuticals (NASDAQ:REGN) has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3691781200186 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.75% during midday trading on Tuesday, hitting $431.38. The company’s stock had a trading volume of 699,266 shares. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The stock’s 50 day moving average is $468.97 and its 200-day moving average is $447.18. The firm has a market cap of $45.74 billion, a P/E ratio of 43.28 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping the consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.82 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals will post $14.90 EPS for the current fiscal year.

A number of analysts have recently issued reports on the company. Morgan Stanley reaffirmed an “equal weight” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 23rd. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 14th. Leerink Swann reaffirmed an “outperform” rating and issued a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 14th. Finally, Citigroup Inc. raised their price objective on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $491.43.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-regeneron-pharmaceuticals-regn-share-price/1574257.html.

In other news, SVP Robert E. Landry sold 663 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total value of $330,571.80. Following the transaction, the senior vice president now owns 10,099 shares of the company’s stock, valued at $5,035,361.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 96,543 shares of company stock worth $46,331,369. Insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.